Among those patients, 138 patients were Luminal (HER2-) subtype, 53 patients were Luminal (HER2+) subtype, 63 patients were HER2 overexpression and 74 patients were triple negative breast cancer. Here, ERBB2 is linked to triple-negative breast carcinoma.